GoodRx Holdings, Inc. revised earnings guidance for the fourth quarter and year ended December 31, 2023. Fourth quarter and full year 2023 revenue and Adjusted Revenue is expected to exceed the November guidance range. Fourth quarter revenue and Adjusted Revenue is expected to be in the range of approximately $195 million to $197 million, an increase of approximately 6% to 7% year-over-year.

Full year 2023 revenue is expected to be in the range of approximately $749 million to $751 million, a decrease of approximately 2% year-over-year. Full year 2023 Adjusted Revenue is expected to be in the range of approximately $759 million to $761 million, a decrease of approximately 1% year-over-year.